Clinical trial
A Multicenter, Open-label, Metabolic Balance Study to Evaluate the Effects of Apraglutide on Intestinal Absorption in Adult Subjects With Short Bowel Syndrome, Intestinal Failure (SBS-IF), and Colon-in-Continuity (CIC)
NCT04964986 is registered in ClinicalTrials.gov with VectivBio AG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open-label, Metabolic Balance Study to Evaluate the Effects of Apraglutide on Intestinal Absorption in Adult Subjects With Short Bowel Syndrome, Intestinal Failure (SBS-IF), and Colon-in-Continuity (CIC)
- Lead sponsor
- VectivBio AG
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 14, 2021
- Completion date
- June 6, 2023
- Enrollment
- 10 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.